ANTI-CANCER THERAPY CONTAINING NATURAL KILLER CELLS AND A FUSION PROTEIN CONTAINING IL-2 PROTEIN AND CD80 PROTEIN

Abstract

The invention relates to an anticancer substance, the active component, comprising NK cells and a fusion protein consisting of IL-2 protein and CD80 protein. Specifically, the fusion protein, comprising CD80 fragment, immunoglobulin Fc, and IL-2 variant, can activate immune cells such as natural killer cells. Furthermore, since cancer can be effectively suppressed when used concurrently with natural killer cells, the drug enhances immune activity in the body, making it effective for cancer treatment due to its high industrial applicability.